LONDON, March 6, 2018 /PRNewswire/ -- Smith & Nephew
(LSE:SN, NYSE:SNN), the global medical technology business, today
announces the full commercial release of bi-cruciate retaining
JOURNEY II XR total knee arthroplasty (TKA) in the United States and Japan.
JOURNEY II XR is the next step in the evolution of total knee
replacement surgery. By retaining, rather than substituting, the
anterior cruciate ligament (ACL) and posterior cruciate ligament
(PCL), JOURNEY II XR is designed to combine the greater patient
satisfaction of a partial knee replacement with the long-term
survivorship and reproducible principles of TKA1-2.
JOURNEY II XR accomplishes this by eliminating the past concerns of
bi-cruciate retaining knees through:
- An implant design that reflects more accurate replication of
the knee anatomy3
- A robust tibial baseplate designed for optimal fixation
and fatigue strength
- The application of Smith & Nephew's VERILAST™ Technology,
an advanced bearing surface designed to provide lasting
survivorship4
- The introduction of enabling technologies such as NAVIO™
robotics-assisted surgery and VISIONAIRE™ patient matched adaptive
guides to help deliver highly reproducible outcomes
Mike Donoghue, Senior Vice
President, Global Orthopaedic Marketing said, "The JOURNEY II XR
knee offers surgeons an innovative treatment option for arthritic
patients who have intact and well-functioning cruciate ligaments.
The retention of the cruciate ligaments may provide patients with
more normal feel and stability throughout the range of motion, and
may lead to a smoother recovery, improved function, and better
patient satisfaction." 3,6-8
JOURNEY II total knee system is designed to achieve normal
shapes, position and motion. Smith & Nephew created this
platform to empower patients to "rediscover normal" following total
knee arthroplasty. The full commercial release of JOURNEY II XR
follows a successful limited market release in both the United States and Japan with more than 70 surgeons in both
countries implanting over 1,100 JOURNEY II XR knees during the last
18 months9. Join Smith & Nephew at the American
Academy of Orthopaedic Surgeons Annual Meeting, Booth #1651 in
New Orleans, LA, March 7-9 to experience the Power of Patient
Satisfaction and elevate what's possible with the JOURNEY II XR
Knee system.
About Smith & Nephew
Smith & Nephew is a
global medical technology business dedicated to helping healthcare
professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound
Management, Sports Medicine and Trauma & Extremities,
Smith & Nephew has around 15,000 employees and a presence in
more than 100 countries. Annual sales in 2017 were almost
$4.8 billion. Smith & Nephew is a
member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith &
Nephew. Certain marks registered US Patent and Trademark
Office.
1. Patient satisfaction after
primary total and unicompartmental knee arthroplasty: an
age-dependent analysis. Von Keudell,
Sodha, Collins, Minas, Fitz, Gomoll; Knee. 2014 Jan;21(1):180-4. 2.
Total knee replacement with retention of both cruciate ligaments: a
22-year follow-up study. P. Sabouret, F. Lavoie, J-M Cloutier Bone
Joint J. 2013 Jul; 95-B(7): 917–922 3. Short-term Range of Motion
is Increased after TKA with an asymmetric bicruciate stabilized
implant. Accepted Poster Presentation, AAOS 2018 New Orleans.
Kaitlin M. Carroll, Peter K. Sculco, Brian CMichaels, Richard L. Murphy, Seth A, Jerabek, David J. Mayman 4. Testing concluded at 45
million cycles, ISO 14242-1 and 14243-3 define test completion at 5
million cycles. 5. Hommel, Hagen, and Kai
Wilke. "Good Early Results Obtained with a Guided-Motion
Implant for Total Knee Arthroplasty: A Consecutive Case Series."
The Open Orthopaedics Journal 11 (2017): 51–56. PMC. Web.
27 Sept. 2017. 6. Kaneko, Takao et
al. Bi-cruciate substituting total knee arthroplasty improved
medio-lateral instability in mid-flexion range. Journal of
Orthopaedics. 14. 201-206. 10.1016 7. Grieco, Trevor F., et al. "In
Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee
Arthroplasty and the Normal Knee Using Fluoroscopy." The Journal of
Arthroplasty, 2017, doi:10.1016/j.arth.2017.09.035.8. Iriuchishima,
Takanori, and Keinosuke Ryu. "A
Comparison of Rollback Ratio between Bicruciate Substituting Total
Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty."
The Journal of Knee Surgery, 2017, doi:10.1055/s-0037-1604445. 9.
Data on file with Smith & Nephew.
View original content with
multimedia:http://www.prnewswire.com/news-releases/smith--nephew-announces-full-commercial-release-of-journey-ii-xr-total-knee-arthroplasty-300608916.html
SOURCE Smith & Nephew